International Cancer Conference Journal最新文献_第7页

A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations. 一例粘液性边界卵巢肿瘤病例报告，复发为高拷贝数改变的浸润性癌。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00722-1

Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai

{"title":"A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations.","authors":"Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai","doi":"10.1007/s13691-024-00722-1","DOIUrl":"10.1007/s13691-024-00722-1","url":null,"abstract":"Mucinous borderline ovarian tumors (MBOTs) have a very low recurrence rate and a good prognosis, especially in the early stages, but some MBOTs occasionally recur with the progression to mucinous ovarian carcinomas (MOCs). Here, we present a case of MBOT that recurred as invasive MOC within 3 years. To examine the reason for the progression from MBOT to MOC, whole-exome sequencing of our case identified identical mutations and copy number alterations in KRAS, CDKN2A, and TP53 in both the MBOT and recurrent MOC. The recurrent MOC had a greater copy number alteration burden compared to the primary MBOT. These findings suggest that MBOT may have progressed to MOC via recurrence, wherein the increased burden of copy number alterations could be its key driver. It was also suggested that TP53 mutations already present in MBOT may contribute to the increased copy number alterations leading to MOC.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00722-1.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"520-524"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report. HER2 阳性转移性乳腺癌患者使用曲妥珠单抗德鲁司坦再治疗的疗效：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-10 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00723-0

Yuko Tanaka, Naoya Ikeda, Seiji Niho, Kazuyuki Ishida

引用次数: 0

Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review. 宫颈癌贝伐单抗化疗期间的继发性自发性气胸：病例报告和文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00696-0

Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao

{"title":"Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review.","authors":"Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao","doi":"10.1007/s13691-024-00696-0","DOIUrl":"10.1007/s13691-024-00696-0","url":null,"abstract":"Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"395-400"},"PeriodicalIF":0.5,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection. 一例通过恩福单抗维多汀显著缩小病灶，并最终完成手术切除的尿路上皮癌的片状扩散病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-31 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00720-3

Kenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, Kentaro Yoshihara, Shutaro Yamamoto, Yu Imai, Kosuke Iwatani, Kojiro Tashiro, Masaya Murakami, Tohru Harada, Takuya Hayashimoto, Miyaka Umemori, Takahiro Kimura, Tatsuya Shimomura, Fumihiko Urabe

{"title":"A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.","authors":"Kenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, Kentaro Yoshihara, Shutaro Yamamoto, Yu Imai, Kosuke Iwatani, Kojiro Tashiro, Masaya Murakami, Tohru Harada, Takuya Hayashimoto, Miyaka Umemori, Takahiro Kimura, Tatsuya Shimomura, Fumihiko Urabe","doi":"10.1007/s13691-024-00720-3","DOIUrl":"10.1007/s13691-024-00720-3","url":null,"abstract":"Secondary extramammary Paget's disease is a rare condition associated with the contiguous extension of tumor cells from the underlying adnexal structures, genitourinary, or gastrointestinal tracts. We report the case of an 80-year-old female with a 7-year history of urothelial carcinoma who presented with erythema of the labia majora. The diagnosis was pagetoid spread of urothelial carcinoma. The patient declined surgical resection of the lesion. She underwent nine cycles of first-line platinum-based chemotherapy and received one course of pembrolizumab for metastatic urothelial carcinoma. As the lesion progressively enlarged, third-line therapy with enfortumab vedotin was initiated, which resulted in significant tumor reduction. This allowed for a successful surgical complete resection of the tumor. Enfortumab vedotin was highly effective and demonstrated dramatic efficacy for controlling extramammary Paget's disease secondary to urothelial carcinoma.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"510-514"},"PeriodicalIF":0.5,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock. 免疫检查点抑制剂相关病窦综合征和心源性休克。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-30 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00718-x

Masatake Kitano, Makiko Yomota, Kansuke Ito, Yukio Hosomi

引用次数: 0

Limb salvage using radical combined hyperthermia and radiotherapy for myxofibrosarcoma of the lower leg in an elderly patient. 使用根治性联合热疗和放疗挽救一名老年小腿肌纤维肉瘤患者的肢体。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-30 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00719-w

Katsuhiro Esaki, Tomoya Matsunobu, Satoshi Nomoto, Yumi Shimohata, Akira Maekawa, Masato Yoshimoto

{"title":"Limb salvage using radical combined hyperthermia and radiotherapy for myxofibrosarcoma of the lower leg in an elderly patient.","authors":"Katsuhiro Esaki, Tomoya Matsunobu, Satoshi Nomoto, Yumi Shimohata, Akira Maekawa, Masato Yoshimoto","doi":"10.1007/s13691-024-00719-w","DOIUrl":"10.1007/s13691-024-00719-w","url":null,"abstract":"Soft tissue sarcomas account for only 1.5% of malignant tumors in adults and are therefore challenging to treat. We present a case of myxofibrosarcoma of the lower leg in an 88-year-old woman who successfully responded to combined hyperthermia and radiotherapy. We proposed a below-knee amputation because of the spread of the lesion, but the patient opted for hyperthermia with radiotherapy. One and a half years later, the tumor partially regrew, and the regrown mass was resected with an R0 margin. Unfortunately, the patient developed a surgical site infection immediately after the resection, and a skin ulcer formed. It took about 2 years for conservative treatment to result in complete ulcer epithelization. The patient has been ambulant, and has not experienced any symptoms of local recurrence or metastasis in the two and a half years since the surgery. Although adverse events related to combined hyperthermia and radiotherapy, such as delayed wound healing, should be considered, it could be an option for the treatment of localized soft-tissue sarcoma, especially in elderly patients.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"499-503"},"PeriodicalIF":0.5,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carcinoma esophagus with small bowel metastasis: a case report with review of literature. 食管癌伴小肠转移：病例报告与文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-27 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00717-y

Vigneshwaran Chandran, Kannan Periasamy, Lileswar Kaman, Kirti Gupta, Uma Nahar

{"title":"Carcinoma esophagus with small bowel metastasis: a case report with review of literature.","authors":"Vigneshwaran Chandran, Kannan Periasamy, Lileswar Kaman, Kirti Gupta, Uma Nahar","doi":"10.1007/s13691-024-00717-y","DOIUrl":"10.1007/s13691-024-00717-y","url":null,"abstract":"Small intestinal metastasis is extremely rare and only 13 cases have been reported till date and almost all such patients have presented with intestinal obstruction. The 5-year overall survival for metastatic esophageal cancer is as low as 5% while the patients with small intestinal metastasis have a median survival of only 3 months (range 1-12 months) despite undergoing radical resection of the small bowel. We present a case of a male in his 50's who presented with difficulty in swallowing for 4 months. On evaluation, he was found to have squamous cell carcinoma in the mid thoracic esophagus. He underwent radical chemo-radiation up to 60 Gy in 25 fractions over 5 weeks. One week after completion of treatment he presented with ileal obstruction and omental nodules and surgical resection and evaluation of the respective ileal segment and omental biopsy revealed a metastatic squamous cell carcinoma. The patient expired 3 months post-surgery. Carcinoma esophagus with small bowel metastasis has a very grave prognosis that patients rarely survive beyond 1 year despite undergoing resection. Hence it is imperative to consider a small bowel metastasis when such patients present with clinical features of intestinal obstruction for early diagnosis and aggressive management.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"449-453"},"PeriodicalIF":0.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase. 使用 EZH2 抑制剂 tazemetostat 治疗处于白血病期的多发性复发滤泡淋巴瘤，获得完全缓解。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-21 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00716-z

Shohei Kikuchi, Yoshimi Nabe, Ryusuke Horaguchi, Tomoki Minemura, Jun Murakami, Akira Noguchi, Kohji Takagi, Yusuke Kamihara, Akinori Wada, Takuma Fujihira, Tsutomu Sato

{"title":"Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase.","authors":"Shohei Kikuchi, Yoshimi Nabe, Ryusuke Horaguchi, Tomoki Minemura, Jun Murakami, Akira Noguchi, Kohji Takagi, Yusuke Kamihara, Akinori Wada, Takuma Fujihira, Tsutomu Sato","doi":"10.1007/s13691-024-00716-z","DOIUrl":"10.1007/s13691-024-00716-z","url":null,"abstract":"Though multiple relapses and serial shortening of remission is one of the characteristics of follicular lymphoma (FL), standard third- and later-line treatments with clear evidence have not yet been established. Tazemetostat, the first oral enhancer of zester homolog 2 (EZH2) inhibitor, showed a favorable clinical outcome and safety profile against relapsed mutant EZH2 FL in a clinical trial and was applied to this clinical setting. Peripheral blood involvement, known as the leukemic phase, was observed in approximately 10% of patients with FL and reported as a poor prognostic factor. However, because of the infrequency of EZH2-activating mutations, clinical data on tazemetostat against FL in the leukemic phase is lacking. Herein, we report a case of multiple relapsed FL in the leukemic phase for which tazemetostat was administered as a sixth-line treatment. Tazemetostat monotherapy showed a slow and sustained clinical efficacy in the leukemic phase as shown by nodal involvement. Circulating lymphoma cells gradually decreased and disappeared in counts after 4 months of treatment. However, circulating lymphoma cells were still detected by flow cytometry up to 6 months of treatment and finally undetected after 9 months. Extended-interval dosing of tazemetostat transformed a partial response into a complete response. Thus, tazemetostat is effective for the treatment of multiple relapsed FL in the leukemic phase.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"488-492"},"PeriodicalIF":0.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib. 早期乳腺癌乳房切除术后放射治疗后的放射性肝炎：难以与阿贝昔单抗导致的药物性肝损伤区分开来。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-19 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00714-1

Shogo Nakamoto, Takahiro Waki, Asuka Mimata, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Tadahiko Shien

{"title":"Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib.","authors":"Shogo Nakamoto, Takahiro Waki, Asuka Mimata, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Tadahiko Shien","doi":"10.1007/s13691-024-00714-1","DOIUrl":"10.1007/s13691-024-00714-1","url":null,"abstract":"Abemaciclib (ABM) is recommended for adjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor type 2-negative early breast cancer (EBC) patients at high risk of recurrence. Here, we present a case of radiation hepatitis challenging to differentiate from drug-induced liver injury during ABM treatment. The patient, a woman in her 40 s, underwent right mastectomy, axillary dissection, and postmastectomy radiation therapy (PMRT) after neoadjuvant chemotherapy for EBC. Subsequently, she received ABM as adjuvant endocrine therapy. Despite suspending ABM due to Grade 3 leukopenia, she developed Grade 3 hepatic dysfunction upon cessation. Based on the dynamic contrast-enhanced computed tomography, we diagnosed the cause of liver dysfunction as radiation hepatitis. Spontaneous improvement allowed us to resume ABM treatment. Clinicians may need to consider radiation hepatitis as a potential cause of hepatic dysfunction in patients who underwent PMRT, along with drug-induced liver injury.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"471-475"},"PeriodicalIF":0.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility preservation in men with hypogonadotropic hypogonadism secondary to germinoma: two cases of gonadotropin replacement therapy before induction of anticancer chemotherapy. 生殖细胞瘤继发性性腺功能减退症男性的生育力保护：两例在诱导抗癌化疗前进行促性腺激素替代治疗的病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-16 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00711-4

Yasuhiro Kaku, Koji Chiba, Yosuke Yamashita, Shun Kawamura, Katsuya Sato, Takuto Hara, Keisuke Okada, Hideaki Miyake

{"title":"Fertility preservation in men with hypogonadotropic hypogonadism secondary to germinoma: two cases of gonadotropin replacement therapy before induction of anticancer chemotherapy.","authors":"Yasuhiro Kaku, Koji Chiba, Yosuke Yamashita, Shun Kawamura, Katsuya Sato, Takuto Hara, Keisuke Okada, Hideaki Miyake","doi":"10.1007/s13691-024-00711-4","DOIUrl":"10.1007/s13691-024-00711-4","url":null,"abstract":"Hypogonadotropic hypogonadism can be caused by brain tumors. For a malignancy such as a germ cell tumor, chemotherapy combined with radiation is administered. In patients who wish for children, the inability to undergo sperm cryopreservation before treatment because of impaired spermatogenesis and/or ejaculation dysfunction can be problematic. We herein present two cases involving a 26-year-old man and a 30-year-old man with hypogonadotropic hypogonadism due to an intracranial germinoma and both wished to have children. Gonadotropin replacement therapy prior to anticancer chemotherapy resulted in subsequent spontaneous pregnancy or assisted reproductive therapy. Subsequent treatment of the tumor resulted in no recurrence for 9 and 2 years, respectively. Close consultation with an oncologist is mandatory in such cases. Depending on the tumor prognosis, however, it may be possible to delay tumor treatment and prioritize fertility because there is a possibility of impaired spermatogenesis due to additional chemotherapy.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"468-470"},"PeriodicalIF":0.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0